Bio-Techne reported fourth-quarter fiscal 2026 revenue of $321.2 million, up 1% as reported and 3% organic, with GAAP EPS of $0.35 versus a loss of $0.11 a year earlier. Adjusted EPS was $0.52, down from $0.53, and full-year adjusted EPS rose to $1.93 from $1.92 on flat revenue of $1.2 billion. The company said it will no longer hold quarterly investor calls because of its pending acquisition by Merck KGaA, Darmstadt, Germany, at $73 per share in cash.
Q4 fiscal 2026 net sales were $321.2 million, up 1% reported and 3% organic.
Q4 GAAP EPS was $0.35 versus $(0.11) a year earlier; adjusted EPS was $0.52 versus $0.53.
Full-year fiscal 2026 net sales were flat at $1.2 billion; full-year adjusted EPS was $1.93 versus $1.92.
Board declared an $0.08 per share dividend, payable September 4, 2026, to holders of record on August 24, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Bio-Techne's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$1.22B
-0.4%
$1.16
+152.2%
15.0%
FY2025
$1.22B
+5.2%
$0.46
-56.2%
6.0%
FY2024
$1.16B
+2.0%
$1.05
-40.3%
14.5%
FY2023
$1.14B
+2.8%
$1.76
+6.0%
25.1%
FY2022
$1.11B
+18.7%
$1.66
+90.8%
24.6%
Frequently asked questions
When is Bio-Techne's next earnings date?
Bio-Techne has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Bio-Techne earn last quarter?
For the quarter ended Sep 2026, Bio-Techne reported diluted EPS of $0.18 (-25.0% year over year) on revenue of $299.71M (+4.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.